Search Results - "Meyer‐Sabellek, W."

Prevalence of extra‐oesophageal manifestations in gastro‐oesophageal reflux disease: an analysis based on the ProGERD Study by Jaspersen, D., Kulig, M., Labenz, J., Leodolter, A., Lind, T., Meyer‐Sabellek, W., Vieth, M., Willich, S. N., Lindner, D., Stolte, M., Malfertheiner, P.

“…Summary Background and aims: Gastro‐oesophageal reflux disease (GERD) can be associated with a variety of extra‐oesophageal disorders (EED) such as chronic…”
Get full text

Quality of life in relation to symptoms in patients with gastro‐oesophageal reflux disease — an analysis based on the ProGERD initiative by Kulig, M., Leodolter, A., Vieth, M., Schulte, E., Jaspersen, D., Labenz, J., Lind, T., Meyer‐Sabellek, W., Malfertheiner, P., Stolte, M., Willich, S. N.

“…Summary Aims : To determine the impact of gastro‐oesophageal reflux disease (GERD) on the quality of life, to assess changes in the quality of life during…”
Get full text

A meta‐analysis comparing eradication, healing and relapse rates in patients with Helicobacter pylori‐associated gastric or duodenal ulcer by Leodolter, A., Kulig, M., Brasch, H., Meyer‐Sabellek, W., Willich, S. N., Malfertheiner, P.

“…Aim: To compare the effectiveness of Helicobacter pylori eradication in curing peptic ulcer disease in trials involving both gastric ulcer and duodenal ulcer…”
Get full text

Cost‐of‐disease analysis in patients with gastro‐oesophageal reflux disease and Barrett's mucosa by WILLICH, S. N., NOCON, M., KULIG, M., JASPERSEN, D., LABENZ, J., MEYER‐SABELLEK, W., STOLTE, M., LIND, T., MALFERTHEINER, P.

“…Summary Background Gastro‐oesophageal reflux disease (GERD) is a common and frequently chronic condition that causes considerable costs. Aim To estimate the…”
Get full text

Long‐term treatment of patients with gastro‐oesophageal reflux disease in routine care – results from the ProGERD study by NOCON, M, LABENZ, J, JASPERSEN, D, MEYER‐SABELLEK, W, STOLTE, M, LIND, T, MALFERTHEINER, P, WILLICH, S. N.

“…Summary Background Gastro‐oesophageal reflux disease (GERD) is a common condition frequently requiring long‐term pharmacological treatment. Aim To describe the…”
Get full text

Histological effects of esomeprazole therapy on the squamous epithelium of the distal oesophagus by VIETH, M., KULIG, M., LEODOLTER, A., NAUCLÉR, E., JASPERSEN, D., LABENZ, J., MEYER‐SABELLEK, W., LIND, T., WILLICH, S., MALFERTHEINER, P., STOLTE, M.

“…Summary Background  Proton pump inhibitor therapy has been reported to reduce proliferative changes of the oesophagus significantly in gastro‐oesophageal…”
Get full text

Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in-Congestive Heart Failure (MERIT-HF) by Herlitz, Johan

“…Metoprolol can improve haemodynamics in chronic heart failure, but survival benefit has not been proven. We investigated whether metoprolol controlled…”
Get full text

Prognostic influence of Barrett’s oesophagus and Helicobacter pylori infection on healing of erosive gastro-oesophageal reflux disease (GORD) and symptom resolution in non-erosive GORD: report from the ProGORD study by Malfertheiner, P, Lind, T, Willich, S, Vieth, M, Jaspersen, D, Labenz, J, Meyer-Sabellek, W, Junghard, O, Stolte, M

“…Background: Adequacy of acid suppression is a critical factor influencing healing in gastro-oesophageal reflux disease (GORD). The European prospective study…”
Get full text

Risk factors of gastroesophageal reflux disease: methodology and first epidemiological results of the ProGERD study by Kulig, M, Nocon, M, Vieth, M, Leodolter, A, Jaspersen, D, Labenz, J, Meyer-Sabellek, W, Stolte, M, Lind, T, Malfertheiner, P, Willich, S.N

“…We describe the design and report the first results of the Progression of Gastroesophageal Reflux Disease (ProGERD) study, to our knowledge the largest…”
Get full text

Long-term clinical course of extra-oesophageal manifestations in patients with gastro-oesophageal reflux disease. A prospective follow-up analysis based on the ProGERD study by Jaspersen, D, Labenz, J, Willich, S N, Kulig, M, Nocon, M, Leodolter, A, Lind, T, Meyer-Sabellek, W, Vieth, M, Stolte, M, Malfertheiner, P

“…Gastro-oesophageal reflux disease can be associated with extra-oesophageal reflux disease such as chronic cough or laryngeal symptoms. The aim of this study…”
Get full text

The effect of adjustable dosing with budesonide/formoterol on health-related quality of life and asthma control compared with fixed dosing by Buhl, R., Kardos, P., Richter, K., Meyer-Sabellek, W., Brüggenjürgen, B., Willich, S. N., Vogelmeier, C.

“…SUMMARY Background: Budesonide/formoterol in a single inhaler is an effective therapy for asthma. We investigated whether adjustable maintenance dosing with…”
Get full text

What parameters are relevant for the histological diagnosis of gastroesophageal reflux disease without Barrett's mucosa? by Vieth, M, Peitz, U, Labenz, J, Kulig, M, Nauclér, E, Jaspersen, D, Meyer-Sabellek, W, Willich, S, Lind, T, Malfertheiner, P, Stolte, M

“…There are still ongoing controversies as to which histological parameters allow the diagnosis of gastroesophageal reflux disease (GERD). The aim of the present…”
Get more information

Antihypertensive and Metabolic Effects of Diltiazem and Nifedipine by SCHULTE, KARL-LUDWIG, MEYER-SABELLEK, WOLFGANG A, HAERTENBERGER, ANGELJKA, THIEDE, HANS-MICHAEL, ROECKER, LOTHAR, DISTLER, ARMIN, GOTZEN, REINHARD

“…The antihypertensive effect of diltiazem (180–270 mg/day) and nifedipine (40–60 mg/day) in slow-release forms was assessed over 8 weeks in a double-blind…”
Get full text

Proposals for European Commission guidelines in the use of ambulatory blood pressure monitoring to evaluate antihypertensive drugs by Meyer-Sabellek, W A

“…Different national authorities have different requirements before antihypertensive drugs can be approved for clinical use. Traditionally, antihypertensive…”
Get more information

Double bolus administration of the novel recombinant plasminogen activator BM 06.022 improves coronary blood flow after reperfusion in a canine model of coronary thrombosis by Martin, U, Sponer, G, König, R, Smolarz, A, Meyer-Sabellek, W, Strein, K

“…Reocclusion of coronary arteries is a major problem after successful thrombolysis in patients with acute myocardial infarction. We evaluated in a canine model…”
Get more information

Blood pressure profile and cardiac risk in hypertensive patients with left ventricular hypertrophy by Meyer-Sabellek, W A, Schulte, K L, Liederwald, K, van Gemmeren, D, Gotzen, R

“…A study of normotensive volunteers and patients with primary hypertension demonstrated the superiority of a single 24-h mean systolic and diastolic ambulatory…”
Get more information

Symptom-guided adjustable dosing asthma therapy with budesonide and formoterol in a single inhaler—The ATACO study by Buhl, R., Kardos, P., Baare, A., Richter, K., Meyer-Sabellek, W., Bruggenjurgen, B., Willich, S.N., Vogelmeier, C.

Get full text

Plasma exchange treatment in autoimmune hemolytic anemia of the warm antibody type with renal failure by von Keyserlingk, H, Meyer-Sabellek, W, Arntz, R, Haller, H

“…A patient with autoimmune hemolytic anemia of the warm antibody type developed a hyperacute hemolytic crisis with acute renal failure under conventional…”
Get more information

Efficacy and Tolerability of Candesartan Cilexetil Monotherapy or in Combination with Other Antihypertensive Drugs: Results of the AURA Study by Schulte, K, Fischer, M, Lenz, T, Meyer-Sabellek, W

Get full text

Open, noncontrolled dose-finding study with a novel recombinant plasminogen activator (BM 06.022) given as a double bolus in patients with acute myocardial infarction by Tebbe, Ulrich, von Essen, Rainer, Smolarz, Adalbert, Limbourg, Peter, Rox, Jürgen, Rüstige, Jörg, Vogt, Albrecht, Wagner, Joachim, Meyer-Sabellek, Wolfgang, Neuhaus, Karl-Ludwig

“…The novel recombinant plasminogen activator (rPA) (BM 06.022) is a mutant of tissue-type plasminogen activator expressed in escherichia coli which can be given…”
Get full text